Semax: The ACTH-Derived Neuropeptide for Cognitive Enhancement, Stroke Recovery, and Brain Resilience

Discovery and Background

Semax, an abbreviation of the Russian phrase for "seven amino acids," is a synthetic heptapeptide with the amino acid sequence Met-Glu-His-Phe-Pro-Gly-Pro (MEHFPGP). It was developed at the Institute of Molecular Genetics of the Russian Academy of Sciences in collaboration with the Institute of Pharmacology in Moscow, emerging from a research program that began in the early 1980s under the direction of Nikolai Myasoedov and colleagues. The Soviet and post-Soviet scientific community had a strong interest in neuroprotective agents driven by the same institutional demands that had produced the bioregulator class: soldiers, cosmonauts, and high-stress workers required cognitive resilience tools with favorable safety profiles that conventional pharmacology could not provide.

The scientific lineage of Semax traces back to the 1950s, when researchers first recognized that ACTH, adrenocorticotropic hormone, had cognitive effects that were entirely distinct from its well-known hormonal role in stimulating cortisol production from the adrenal glands. ACTH is a 39-amino acid peptide produced by the pituitary gland that acts primarily on the adrenal cortex, but research demonstrated that fragments of ACTH, particularly the region spanning positions 4 through 10 of the sequence, retained neurotrophic and behavioral effects without triggering the hormonal cascade associated with the full molecule. Several derivatives of this ACTH fragment were explored over the following decades, with the key breakthrough coming from the addition of a C-terminal Pro-Gly-Pro tripeptide. This modification dramatically extended the biological activity of the ACTH(4-7) fragment from a half-life of minutes to approximately 20 to 24 hours in animal models, a change that made the compound practical for therapeutic use.

Semax was first described in the scientific literature in 1991 and became a registered prescription medication in Russia and Ukraine, where it is approved for the treatment of ischemic brain stroke, dyscirculatory encephalopathy, optic nerve atrophy, cognitive disorders including dementia, and neurological deficits in newborns. It was added to the Russian List of Vital and Essential Drugs by the Russian Federation government in December 2011, reflecting its established role in Russian clinical neurology. Outside of Russia and Eastern Europe, Semax has not been evaluated or approved by regulatory bodies including the FDA, though it has attracted growing attention in the biohacking, nootropic, and research peptide communities and is available through compounding pharmacies in some markets.

The compound's defining characteristic is its structural separation of ACTH's neurotrophic and hormonal activities. The ACTH(4-7) fragment that forms Semax's N-terminus does not interact with the MC2 receptor through which ACTH stimulates cortisol production, and Semax has been confirmed to be entirely devoid of hormonal activity in standard endocrinological assays. What it retains, and in some respects amplifies, is ACTH's capacity to support neuronal survival, stimulate neurotrophic factor production, and modulate neurotransmitter systems in the brain.

Research Overview

The research base for Semax is primarily concentrated in the Russian scientific literature, with a more limited but growing body of English-language publications from independent research groups. The compound has been studied across a range of neurological contexts including stroke, traumatic brain injury, cognitive enhancement in healthy subjects, optic nerve disease, Parkinson's disease, Alzheimer's disease, ADHD, anxiety, and depression.

The most consistently documented finding in the Semax literature is its capacity to elevate brain-derived neurotrophic factor (BDNF) rapidly and significantly in multiple brain regions following administration. In animal studies, intranasal Semax increases BDNF and its signaling receptor TrkB in the hippocampus within three hours of administration, and elevates BDNF and nerve growth factor (NGF) in both the frontal cortex and hippocampus at eight hours post-dose. These neurotrophic factor elevations are mechanistically linked to the cognitive, neuroprotective, and neurorestorative effects that define Semax's profile across multiple research contexts.

The most significant human clinical investigation of Semax is a study in 110 stroke patients published in the Russian neurological literature and referenced in multiple English-language reviews. Patients receiving two 10-day courses of intranasal Semax at 6,000 micrograms per day, with a 20-day interval between courses, showed significantly increased plasma BDNF levels throughout the treatment period regardless of the timing of their rehabilitation program. High BDNF levels were associated with accelerated and improved functional recovery as measured by the Barthel index, a validated scale of functional independence, with a positive correlation confirmed between BDNF plasma levels and Barthel scores throughout follow-up. Motor performance improved significantly in Semax-treated patients compared to controls.

A 2018 pilot study in 24 healthy subjects found that intranasal Semax at a total dose of 1.2 mg increased resting fMRI signal in the default mode network rostral subcomponent relative to placebo, providing the first human neuroimaging evidence of Semax's effects on brain activity in healthy individuals. Separate human studies in healthy subjects confirmed that Semax at doses of 250 to 1,000 micrograms per kilogram improved attention and short-term memory and produced EEG changes characteristic of neuroprotective drugs. A genome-wide transcriptional analysis of Semax effects in rat brain ischemia identified modulation of over 1,500 genes, with the most pronounced effects on immune system gene expression, vascular gene expression, and neurotransmitter signaling pathways, painting a picture of broad transcriptional influence rather than a single targeted mechanism.

In Alzheimer's disease models, a 2024 study in APP/PS1 transgenic mice, a standard model of amyloid pathology, found that both Semax and a modified derivative improved cognitive functions in open field, novel object recognition, and Barnes maze behavioral tests, and histological examination showed reduced amyloid inclusions in both the cortex and hippocampus of treated animals. In optic nerve disease, clinical trials using Semax eye drops at 0.1% concentration demonstrated improvements in visual field parameters, contrast sensitivity, and visual evoked potential latencies in patients with optic nerve atrophy and ischemic optic neuropathy. A pilot study in 45 children with ADHD found that intranasal Semax improved attention span, reduced impulsivity, and enhanced academic performance as rated by parents and teachers on standardized scales.

Key Mechanisms

BDNF and TrkB Upregulation via CREB Activation

Semax's most thoroughly documented and mechanistically significant effect is the upregulation of brain-derived neurotrophic factor through activation of CREB, the cAMP response element-binding protein that serves as a master transcriptional regulator of neurotrophic factor gene expression. BDNF is the most abundant and broadly important neurotrophic factor in the adult brain, supporting the survival of existing neurons, promoting neurogenesis in the hippocampus, driving synaptic plasticity and long-term potentiation, and maintaining the dendritic complexity that underlies cognitive function. CREB activation by Semax triggers increased BDNF mRNA transcription in the hippocampus, prefrontal cortex, and striatum, leading to elevated BDNF protein levels that activate the TrkB receptor. TrkB activation then initiates downstream signaling through MAPK/ERK, PI3K/AKT, and PLCgamma pathways, collectively promoting neuronal survival, synaptic strengthening, dendritic arborization, and hippocampal neurogenesis. The upregulation of TrkB receptor expression alongside BDNF, rather than BDNF alone, represents a particularly important feature: it ensures that the signal transduction machinery required to respond to increased BDNF is simultaneously amplified.

Dopaminergic and Serotonergic Modulation

Semax activates both dopaminergic and serotonergic brain systems through mechanisms that include upregulation of tyrosine hydroxylase, the rate-limiting enzyme in dopamine biosynthesis, leading to increased extracellular dopamine concentrations in the striatum and nucleus accumbens. These are brain regions central to motivation, reward processing, attention, and motor control, explaining the observed effects on focus, motivation, and cognitive processing speed. In the serotonergic system, Semax increases serotonin turnover and enhances serotonergic neurotransmission in the hippocampus and prefrontal cortex, contributing to antidepressant-like and anxiolytic-like effects documented across multiple animal models. The dopaminergic activation also provides a mechanistic basis for its potential relevance in ADHD, where dopamine signaling in the prefrontal cortex is a central therapeutic target, and in Parkinson's disease, where dopaminergic neuron preservation is the primary clinical goal.

Enkephalinase Inhibition and Endogenous Opioid Preservation

Both Semax and the related peptide Selank inhibit enkephalinase enzymes, the proteases responsible for degrading enkephalins and other endogenous regulatory peptides in the brain. Enkephalins are endogenous opioid neuropeptides that modulate pain perception, stress response, emotional regulation, and reward circuitry through mu and delta opioid receptor activation. By inhibiting their degradation, Semax effectively increases the available pool of endogenous enkephalins without directly activating opioid receptors, producing modulatory effects on pain, mood, and stress resilience through an endogenous substrate rather than an exogenous agonist. This mechanism is pharmacologically distinct from the BDNF pathway and provides a complementary explanation for some of Semax's analgesic and anxiolytic effects.

Melanocortin Receptor Interaction

Evidence suggests that Semax may interact with melanocortin receptors, particularly MC4 and MC5, where it has been shown to act as an antagonist or partial agonist, competitively blocking the action of alpha-MSH. This receptor interaction is mechanistically interesting given the shared molecular ancestry between Semax and alpha-MSH, both being derived from the POMC precursor protein, and may contribute to some of Semax's anti-inflammatory and stress-modulatory effects that are observed in addition to its neurotrophic actions. The clinical significance of this melanocortin receptor interaction remains an active area of investigation, and the precise binding profile across the full melanocortin receptor family has not been comprehensively characterized.

Broad Transcriptional Modulation in Ischemia

The genome-wide transcriptional analysis in rat focal ischemia revealed that Semax's neuroprotective effects in stroke conditions operate through broad gene expression remodeling rather than a single targeted mechanism. Semax enhanced the expression of genes related to immune system activation and mobilization, chemokine signaling, vascular stabilization, and neurotransmitter system maintenance, while simultaneously suppressing the inflammatory pathways, apoptotic signaling, and immune cell degranulation that drive secondary neuronal death in the ischemic penumbra. The GSEA analysis identified upregulation of neuronal system gene sets, G-protein-coupled receptor signaling, and chemical synapse transmission, alongside downregulation of innate immune activation, cytokine signaling, and p53-dependent apoptosis. This transcriptional pattern is consistent with a compound that actively promotes neuronal recovery while limiting the immune-mediated secondary injury that destroys viable tissue in the penumbral zone surrounding the ischemic core.

Calcium Dynamics in Hippocampal Neurons

Semax at one micromolar concentration was found to significantly increase the frequency of spontaneous intracellular calcium fluctuations in pyramidal neurons of the hippocampal CA1 field, without affecting proton-stimulated calcium entry in cerebellar granule cells. This selective modulation of hippocampal calcium dynamics, the region most directly implicated in memory formation and cognitive function, provides insight into the cellular targets and initial stages of Semax's interaction with the hippocampal neuronal network and offers a mechanistic link between the peptide's biochemical effects and its documented improvements in spatial learning and memory tasks.

Common Applications

Stroke Recovery and Acute Neuroprotection

The most extensively clinically validated application of Semax, and its primary approved use in Russia, is in the treatment and recovery from ischemic stroke. The combination of BDNF elevation that drives functional neuronal recovery, broad transcriptional modulation that limits secondary ischemic injury, vascular gene expression changes that support collateral circulation, and immune system activation that promotes tissue clearance and repair creates a comprehensive neuroprotective and neurorestorative profile that operates across multiple stages of the post-stroke recovery process. The 110-patient clinical study demonstrating BDNF elevation and improved Barthel index scores across both early and late rehabilitation groups provides the most clinically meaningful human evidence in the Semax literature. Intranasal administration is the predominant route in stroke recovery applications, with typical protocols involving twice-daily administration of one to two drops of the standard concentration solution to each nostril for 10 to 14 day courses. Semax is commonly paired with Selank in neurological recovery protocols, where Semax's stimulatory neurotrophic effects are balanced by Selank's anxiolytic and GABA-modulating properties.

Cognitive Enhancement and Nootropic Use

Outside of clinical neurological applications, Semax is most widely used as a cognitive enhancer in healthy individuals seeking improvements in attention, working memory, processing speed, and mental clarity. The mechanisms supporting this application are well grounded: BDNF elevation drives synaptic plasticity and long-term potentiation in hippocampal and prefrontal circuits, dopaminergic enhancement improves prefrontal executive function and attentional control, and the rapid onset of subjective cognitive effects, reported within 30 minutes of intranasal administration in many users, is consistent with the acute dopaminergic and calcium dynamic effects that operate faster than the hours-long timescale of neurotrophic factor gene expression changes. Human studies in healthy subjects confirming improvements in attention, short-term memory, and EEG patterns characteristic of cognitive engagement provide supportive evidence, though the evidence base for this application in healthy individuals remains smaller than for stroke contexts.

Optic Nerve Disease and Visual Function

Semax's clinical use in optic nerve atrophy and ischemic optic neuropathy represents one of the more concrete and clinically documented applications in its Russian regulatory profile. The neuroprotective mechanism is consistent with its broader neuronal protection profile: BDNF and NGF upregulation support retinal ganglion cell survival and optic nerve fiber maintenance, while improved microcirculation reduces ischemic stress on vulnerable optic nerve tissue. Clinical trials using Semax eye drops demonstrated improvements in visual field parameters, contrast sensitivity, and visual evoked potential latencies, providing objective electrophysiological evidence of functional improvement rather than simply subjective symptom reporting.

Anxiety, Depression, and Stress Resilience

Semax's serotonergic modulation, BDNF elevation, and enkephalinase inhibition collectively support a role in the management of anxiety and depression that goes beyond simple symptomatic relief and addresses some of the underlying neurobiological deficits associated with these conditions. BDNF deficiency is strongly implicated in both anxiety and depression, and its restoration is now understood as a shared mechanism among multiple effective antidepressant approaches including SSRIs, exercise, and ketamine. Semax's capacity to rapidly elevate BDNF provides a mechanistic rationale for its antidepressant and anxiolytic properties that is grounded in established neurobiology. Animal studies confirming normalization of chronic stress-induced behavioral changes, combined with the enkephalinase inhibition that preserves endogenous opioid tone, support this application, though formal randomized controlled trial data in human anxiety and depression populations is limited.

ADHD and Attention Disorders

The combination of dopaminergic enhancement in prefrontal circuits and BDNF-driven improvements in synaptic function creates a mechanistic rationale for Semax's potential in ADHD that is distinct from conventional stimulant pharmacology. Where methylphenidate and amphetamine derivatives work primarily by blocking dopamine and norepinephrine reuptake to flood the synapse with catecholamines, Semax's approach is to support the upstream biosynthesis and neurotrophic maintenance of the dopaminergic system. The pilot study in 45 children showing improvements in attention, impulsivity, and academic performance using age-adjusted intranasal doses provides preliminary clinical support, and Semax is reportedly used for ADHD in Russian clinical practice. The theoretical advantage of an approach that works through neurotrophic support rather than forced catecholamine release is the absence of stimulant-class adverse effects including insomnia, cardiovascular stress, appetite suppression, and addiction potential.

Neurodegenerative Disease Prevention and Management

The reduction of amyloid inclusions in both cortex and hippocampus of APP/PS1 transgenic mice, combined with significant improvements across multiple behavioral measures of cognitive function in this Alzheimer's disease model, establishes a compelling preclinical case for Semax's relevance in neurodegenerative disease. The mechanism involves BDNF-mediated promotion of non-amyloidogenic APP processing, suppression of neuroinflammatory pathways that accelerate amyloid pathology, and preservation of the synaptic architecture that amyloid plaques progressively destroy. For Parkinson's disease, the dopaminergic neuroprotective effects and the preliminary evidence from MPTP model studies suggesting partial behavioral protection provide a rationale for investigation, though results in Parkinson's disease models have been mixed and the application requires further study.

References

1. https://pmc.ncbi.nlm.nih.gov/articles/PMC3987924/
2. https://www.mdpi.com/2073-4425/11/6/681
3. https://pubmed.ncbi.nlm.nih.gov/29798983/
4. https://actanaturae.ru/2075-8251/article/view/27808
5. https://www.alzdiscovery.org/uploads/cognitive_vitality_media/Semax-Cognitive-Vitality-For-Researchers.pdf
6. https://link.springer.com/article/10.1007/s10517-025-06501-z

Note: This list compiles unique sources referenced throughout the article. For a full bibliography, including additional studies mentioned in the content, consult the original research compilations or databases like PubMed.